Sunitinib

Search with Google Search with Bing

Information
Drug Name
Sunitinib
Description
Entry(CIViC)
50
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
angiosarcoma KDR p.Ala1065Thr (p.A1065T)
( ENST00000263923.5 ) KDR p.Ala1065Thr (p.A1065T)
( ENST00000263923.5 ) 		D Predictive Supports Sensitivity/Response Somatic 3 19723655 Detail
angiosarcoma KDR p.Asp717Val (p.D717V)
( ENST00000263923.5 ) KDR p.Asp717Val (p.D717V)
( ENST00000263923.5 ) 		D Predictive Supports Sensitivity/Response Somatic 3 19723655 Detail
gastrointestinal stromal tumor KIT EXON 9 MUTATION KIT EXON 9 MUTATION B Predictive Supports Sensitivity/Response Somatic 3 22439647 Detail
melanoma KIT EXON 11 MUTATION KIT EXON 11 MUTATION C Predictive Supports Sensitivity/Response Somatic 3 22261812 Detail
renal cell carcinoma FLT3 p.Thr227Met (p.T227M)
( ENST00000241453.12 ) FLT3 p.Thr227Met (p.T227M)
( ENST00000241453.12 ) 		B Predictive Supports Adverse Response Common Germline 3 19667267 Detail
gastrointestinal stromal tumor KIT EXON 9 MUTATION KIT EXON 9 MUTATION B Predictive Supports Sensitivity/Response Somatic 3 18955458 Detail
papillary adenocarcinoma RET OVEREXPRESSION
( ENST00000355710.8 ) RET OVEREXPRESSION
( ENST00000355710.8 ) 		C Predictive Supports Sensitivity/Response Somatic 3 20696054 Detail
B-cell adult acute lymphocytic leukemia FLT3 OVEREXPRESSION
( ENST00000241453.12 ) FLT3 OVEREXPRESSION
( ENST00000241453.12 ) 		C Predictive Supports Sensitivity/Response Somatic 3 27181063 Detail
lung non-small cell carcinoma PDGFRA AMPLIFICATION
( ENST00000257290.10 ) PDGFRA AMPLIFICATION
( ENST00000257290.10 ) 		D Predictive Supports Sensitivity/Response Somatic 3 19366796 Detail
angiosarcoma PTPRB LOSS-OF-FUNCTION PTPRB LOSS-OF-FUNCTION D Predictive Supports Sensitivity/Response Somatic 3 24633157 Detail
high grade glioma IDH1 R132 IDH1 R132 B Predictive Supports Sensitivity/Response Somatic 2 22199315 Detail
melanoma KIT p.Asp821Tyr (p.D821Y)
( ENST00000412167.7, ENST00000689832.1, ENST00000288135.6, ENST00000687246.1, ENST00000686011.1, ENST00000687109.1, ENST00000687295.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp821Tyr (p.D821Y)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Somatic 2 19035443 Detail
acute myeloid leukemia FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		D Predictive Does Not Support Sensitivity/Response Somatic 3 15304385 Detail
acute myeloid leukemia FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		D Predictive Supports Sensitivity/Response Somatic 2 15304385 Detail
acute myeloid leukemia FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		D Predictive Supports Sensitivity/Response Somatic 2 15304385 Detail
cancer KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val560Asp (p.V560D)
( ENST00000690543.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 16046538 Detail
gastrointestinal stromal tumor KIT p.Val655Ala (p.V655A)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val655Ala (p.V655A)
( ENST00000689832.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		B Predictive Supports Sensitivity/Response Somatic 3 16638875 Detail
acute myeloid leukemia FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		C Predictive Supports Sensitivity/Response Somatic 15459012 Detail
cancer PDGFRA p.Val561Asp (p.V561D), ENSG00000282278 c.1018-56T>A
( ENST00000257290.10 ) PDGFRA p.Val561Asp (p.V561D), ENSG00000282278 c.1018-56T>A
( ENST00000257290.10 ) 		D Predictive Does Not Support Resistance Somatic 2 18955458 Detail
cancer PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V)
( ENST00000257290.10 ) PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V)
( ENST00000257290.10 ) 		D Predictive Supports Resistance Somatic 2 18955458 Detail
gastrointestinal stromal tumor KIT p.Lys551_Lys559del (p.K551_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys551_Lys559del (p.K551_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		C Predictive Supports Resistance Somatic 2 18955458 Detail
gastrointestinal stromal tumor KIT EXON 11 MUTATION KIT EXON 11 MUTATION B Predictive Supports Resistance Somatic 3 18955458 Detail
cancer KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Resistance Somatic 2 18955458 Detail
gastrointestinal stromal tumor KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000687109.1, ENST00000687246.1 ) KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		C Predictive Supports Resistance Somatic 3 18955458 Detail
gastrointestinal stromal tumor KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000687109.1, ENST00000687246.1 ) KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 25239608 Detail
gastrointestinal stromal tumor KIT p.Lys559_Val560del (p.K559_V560del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys559_Val560del (p.K559_V560del)
( ENST00000288135.6, ENST00000692783.1, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1 ) 		C Predictive Supports Resistance Somatic 2 18955458 Detail
cancer KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Resistance Somatic 2 18955458 Detail
gastrointestinal stromal tumor KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		C Predictive Supports Resistance Somatic 3 18955458 Detail
gastrointestinal stromal tumor KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Leu577Pro (p.L577P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Leu577Pro (p.L577P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		C Predictive Supports Resistance Somatic 2 18955458 Detail
gastrointestinal stromal tumor KIT p.Asp580del (p.D580del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp580del (p.D580del)
( ENST00000412167.7, ENST00000288135.6, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		C Predictive Supports Resistance Somatic 2 18955458 Detail
gastrointestinal stromal tumor KIT P551_E554delPMYE KIT P551_E554delPMYE D Predictive Does Not Support Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 4 25239608 Detail
gastrointestinal stromal tumor KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V)
( ENST00000257290.10 ) PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V)
( ENST00000257290.10 ) 		C Predictive Supports Resistance Somatic 3 18955458 Detail
gastrointestinal stromal tumor KIT V569_L576DEL KIT V569_L576DEL B Predictive Supports Sensitivity/Response Somatic 3 26772734 Detail
gastrointestinal stromal tumor KIT p.Asp817Glu (p.D817E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp817Glu (p.D817E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Resistance Somatic 4 25239608 Detail
renal cell carcinoma BAP1 MUTATION BAP1 MUTATION B Predictive Supports Resistance Somatic 4 27751729 Detail
gastrointestinal stromal tumor KIT UNKNOWN KIT W557_V559insC C Predictive Supports Resistance Somatic 2 18955458 Detail
gastrointestinal stromal tumor KIT p.Lys551_Val560del (p.K551_V560del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys551_Val560del (p.K551_V560del)
( ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1 ) 		C Predictive Does Not Support Resistance Somatic 2 18955458 Detail
acute myeloid leukemia KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Sensitivity/Response Somatic 3 21482694 Detail
acute myeloid leukemia FGFR1 FGFR1 FUSIONS FGFR1 FGFR1 FUSIONS D Predictive Does Not Support Sensitivity/Response Somatic 3 21482694 Detail
acute myeloid leukemia PDGFRA FIP1L1-PDGFRA D Predictive Supports Sensitivity/Response Somatic 3 21482694 Detail
leukemia FLT3 ITD FLT3 ITD D Predictive Supports Sensitivity/Response Somatic 4 21482694 Detail
gastrointestinal stromal tumor KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 2 25239608 Detail
gastrointestinal stromal tumor KIT p.Lys643Glu (p.K643E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys643Glu (p.K643E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Sensitivity/Response Somatic 3 25239608 Detail
gastrointestinal stromal tumor KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Resistance Somatic 4 25239608 Detail
gastrointestinal stromal tumor KIT p.Ala830Pro (p.A830P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala830Pro (p.A830P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Supports Resistance Somatic 4 25239608 Detail
gastrointestinal stromal tumor KIT p.Thr671Ile (p.T671I)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Thr671Ile (p.T671I)
( ENST00000412167.7, ENST00000288135.6, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		D Predictive Does Not Support Resistance Somatic 5 25239608 Detail
renal cell carcinoma HMOX1 EXPRESSION HMOX1 EXPRESSION B Predictive Supports Resistance N/A 3 26309414 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
COS-7 cells were transiently transfected with expr... KDR KDR p.Ala1065Thr (p.A1065T)
( ENST00000263923.5 ) KDR p.Ala1065Thr (p.A1065T)
( ENST00000263923.5 ) 		Sensitivity true CIViC Evidence detail
COS-7 cells were transiently transfected with expr... KDR KDR p.Asp717Val (p.D717V)
( ENST00000263923.5 ) KDR p.Asp717Val (p.D717V)
( ENST00000263923.5 ) 		Sensitivity true CIViC Evidence detail
Primary tumor genotyping of 89 patients with metas... KIT KIT EXON 9 MUTATION KIT EXON 9 MUTATION Sensitivity true CIViC Evidence detail
10 melanoma patients were evaluated after sunitini... KIT KIT EXON 11 MUTATION KIT EXON 11 MUTATION Sensitivity true CIViC Evidence detail
In 219 patients with mostly Renal Cell Carcinoma a... FLT3 FLT3 p.Thr227Met (p.T227M)
( ENST00000241453.12 ) FLT3 p.Thr227Met (p.T227M)
( ENST00000241453.12 ) 		Adverse Response true CIViC Evidence detail
In a study of 78 patients with gastrointestinal st... KIT KIT EXON 9 MUTATION KIT EXON 9 MUTATION Sensitivity true CIViC Evidence detail
A 78-year-old man presented with oral papillary ad... RET RET OVEREXPRESSION
( ENST00000355710.8 ) RET OVEREXPRESSION
( ENST00000355710.8 ) 		Sensitivity true CIViC Evidence detail
A 25-year-old Caucasian male presented with a seco... FLT3 FLT3 OVEREXPRESSION
( ENST00000241453.12 ) FLT3 OVEREXPRESSION
( ENST00000241453.12 ) 		Sensitivity true CIViC Evidence detail
In the sunitinib-sensitive adenosquamous NSCLC cel... PDGFRA PDGFRA AMPLIFICATION
( ENST00000257290.10 ) PDGFRA AMPLIFICATION
( ENST00000257290.10 ) 		Sensitivity true CIViC Evidence detail
The endothelial phosphatase PTPRB, a negative regu... PTPRB PTPRB LOSS-OF-FUNCTION PTPRB LOSS-OF-FUNCTION Sensitivity true CIViC Evidence detail
In a clinical study of 63 recurrent glioma patient... IDH1 IDH1 R132 IDH1 R132 Sensitivity true CIViC Evidence detail
28 acral or mucosal melanomas were examined for KI... KIT KIT p.Asp821Tyr (p.D821Y)
( ENST00000412167.7, ENST00000689832.1, ENST00000288135.6, ENST00000687246.1, ENST00000686011.1, ENST00000687109.1, ENST00000687295.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp821Tyr (p.D821Y)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		N/A true CIViC Evidence detail
Murine Ba/F3 cells with FLT3 D835V mutation were a... FLT3 FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		Sensitivity false CIViC Evidence detail
SU11248 + Cytarabin has a synergic effect on Murin... FLT3 FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		Sensitivity true CIViC Evidence detail
SU11248 + Daunorubicin has a synergic effect on Mu... FLT3 FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		Sensitivity true CIViC Evidence detail
KIT(V559D) were expressed in HEK-293 cells (in vit... KIT KIT p.Val560Asp (p.V560D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val560Asp (p.V560D)
( ENST00000690543.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
In GIST tumor cells and patients harboring KIT V65... KIT KIT p.Val655Ala (p.V655A)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val655Ala (p.V655A)
( ENST00000689832.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
In a retrospective study of 15 acute myeloid leuke... FLT3 FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) FLT3 p.Asp835Val (p.D835V)
( ENST00000241453.12 ) 		Sensitivity true CIViC Evidence detail
In an in vitro study, Chinese hamster ovary cells ... PDGFRA PDGFRA p.Val561Asp (p.V561D), ENSG00000282278 c.1018-56T>A
( ENST00000257290.10 ) PDGFRA p.Val561Asp (p.V561D), ENSG00000282278 c.1018-56T>A
( ENST00000257290.10 ) 		Resitance or Non-Reponse false CIViC Evidence detail
In an in vitro study, Chinese hamster ovary cells ... PDGFRA PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V)
( ENST00000257290.10 ) PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V)
( ENST00000257290.10 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Patient 3 from a larger cohort of genotyped patien... KIT KIT p.Lys551_Lys559del (p.K551_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys551_Lys559del (p.K551_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In a phase I/II trial of sunitinib efficacy on ima... KIT KIT EXON 11 MUTATION KIT EXON 11 MUTATION Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, Chinese hamster ovary cells ... KIT KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
Patients 11, 69, and 73 from a larger cohort of ge... KIT KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000687109.1, ENST00000687246.1 ) KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000687109.1, ENST00000687246.1 ) KIT p.Trp558_Lys559del (p.W558_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
Patient 47 from a larger cohort of genotyped patie... KIT KIT p.Lys559_Val560del (p.K559_V560del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys559_Val560del (p.K559_V560del)
( ENST00000288135.6, ENST00000692783.1, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, Chinese hamster ovary cells ... KIT KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
Patient 72 from a larger cohort of genotyped patie... KIT KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Val561Asp (p.V561D)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
Patient 29 from a larger cohort of genotyped patie... KIT KIT p.Leu577Pro (p.L577P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Leu577Pro (p.L577P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Patient 74 from a larger cohort of genotyped patie... KIT KIT p.Asp580del (p.D580del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp580del (p.D580del)
( ENST00000412167.7, ENST00000288135.6, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT P551_E554delPMYE KIT P551_E554delPMYE Sensitivity false CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Pro552_Lys559del (p.P552_K559del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independent Ba/F3 cel... KIT KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys559delinsAsnPro (p.K559delinsNP)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
Patients 29 and 66 from a larger cohort of genotyp... PDGFRA PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V)
( ENST00000257290.10 ) PDGFRA p.Asp842Val (p.D842V), ENSG00000282278 p.Asp602Val (p.D602V)
( ENST00000257290.10 ) 		Resitance or Non-Reponse true CIViC Evidence detail
This study (NCT01459757) is a retrospective analys... KIT KIT V569_L576DEL KIT V569_L576DEL Sensitivity true CIViC Evidence detail
Several preclinical studies were done in order to ... KIT KIT p.Asp817Glu (p.D817E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asp817Glu (p.D817E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
This study evaluated the effects of everolimus and... BAP1 BAP1 MUTATION BAP1 MUTATION Resitance or Non-Reponse true CIViC Evidence detail
Patient 36 from a larger cohort of genotyped patie... KIT KIT UNKNOWN KIT W557_V559insC Resitance or Non-Reponse true CIViC Evidence detail
Patient 78 from a larger cohort of genotyped patie... KIT KIT p.Lys551_Val560del (p.K551_V560del)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys551_Val560del (p.K551_V560del)
( ENST00000689994.1, ENST00000690543.1, ENST00000692783.1, ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
In a preclinical trial, the AML cell line Kasumi-1... KIT KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity false CIViC Evidence detail
In a preclinical trial, the AML cell line KG1 with... FGFR1 FGFR1 FGFR1 FUSIONS FGFR1 FGFR1 FUSIONS Sensitivity false CIViC Evidence detail
In a preclinical trial, the AML cell line EOL1with... PDGFRA PDGFRA FIP1L1-PDGFRA Sensitivity true CIViC Evidence detail
In a preclinical trial, the leukemic cell line MV4... FLT3 FLT3 ITD FLT3 ITD Sensitivity true CIViC Evidence detail
In an in vitro study, an IL3 independant Ba/F3 cel... KIT KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala503_Tyr504insAlaTyr (p.A503_Y504insAY)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
The GIST882 patient derived cell line expressing K... KIT KIT p.Lys643Glu (p.K643E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Lys643Glu (p.K643E)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Sensitivity true CIViC Evidence detail
Several preclinical studies tested the effects of ... KIT KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687246.1, ENST00000687109.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Asn823Lys (p.N823K)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Several preclinical studies tested the effects of ... KIT KIT p.Ala830Pro (p.A830P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Ala830Pro (p.A830P)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse true CIViC Evidence detail
Several preclinical studies tested the effects of ... KIT KIT p.Thr671Ile (p.T671I)
( ENST00000288135.6, ENST00000412167.7, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) KIT p.Thr671Ile (p.T671I)
( ENST00000412167.7, ENST00000288135.6, ENST00000686011.1, ENST00000687109.1, ENST00000687246.1, ENST00000687295.1, ENST00000689832.1, ENST00000689994.1, ENST00000690543.1, ENST00000692783.1 ) 		Resitance or Non-Reponse false CIViC Evidence detail
In 66 patients with advanced renal cell carcinoma,... HMOX1 HMOX1 EXPRESSION HMOX1 EXPRESSION Resitance or Non-Reponse true CIViC Evidence detail
Acral lentiginous melanoma. Sunitinib is a small m... KIT KIT D820Y Sensitivity true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT01621568 Active, not recruiting Phase 2 Sunitinib for Advanced Thymus Cancer Following Earlier Treatment May 15, 2012 July 31, 2024
NCT06390826 Active, not recruiting Phase 2 Testing Sunitinib as Potentially Targeted Treatment in Cancers With cKIT Genetic Changes (MATCH - Subprotocol V) August 11, 2015 March 24, 2025
NCT01396408 Active, not recruiting Phase 2 A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours February 9, 2012 December 31, 2024
NCT03905889 Active, not recruiting Phase 1 A Study of Abemaciclib in Combination With Sunitinib in Metastatic Renal Cell Carcinoma June 5, 2019 November 5, 2024
NCT02811861 Active, not recruiting Phase 3 Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma October 13, 2016 July 31, 2024
NCT04394975 Active, not recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer August 20, 2020 June 30, 2023
NCT01391962 Active, not recruiting Phase 2 Sunitinib or Cediranib for Alveolar Soft Part Sarcoma July 18, 2011 March 15, 2025
NCT03673501 Active, not recruiting Phase 3 A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib February 8, 2019 December 2024
NCT00381641 Active, not recruiting Phase 2 Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery August 8, 2006 March 8, 2025
NCT00715442 Active, not recruiting Phase 2 Pre-Surgical Sutent in Renal Cell Carcinoma (RCC) June 24, 2008 June 30, 2025
NCT03091192 Active, not recruiting Phase 3 Savolitinib vs. Sunitinib in MET-driven PRCC. July 25, 2017 December 31, 2024
NCT02231749 Active, not recruiting Phase 3 Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214) October 16, 2014 August 7, 2027
NCT02068586 Active, not recruiting Phase 2 Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma November 19, 2014 December 31, 2025
NCT02853331 Active, not recruiting Phase 3 Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426) September 16, 2016 December 31, 2025
NCT01306045 Active, not recruiting Phase 2 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies February 8, 2011 December 31, 2024
NCT03260894 Active, not recruiting Phase 3 Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302) December 7, 2017 December 31, 2024
NCT03141177 Active, not recruiting Phase 3 A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma August 22, 2017 April 17, 2024
NCT02684006 Active, not recruiting Phase 3 A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101) March 23, 2016 May 21, 2024
NCT00510640 Completed Phase 2 Thyroid Cancer and Sunitinib August 2007 March 2012
NCT00056693 Completed Phase 2 Treatment With SU11248 in Patients With Neuroendocrine Tumors April 2003 September 2006
NCT00543049 Completed Phase 2 Randomized Multicenter Trial With SU11248 Evaluating Dosage,Tolerability,Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor September 2007
NCT00543504 Completed Phase 1 Bevacizumab in Multiple Phase I Combinations October 10, 2007 April 29, 2020
NCT00553696 Completed Phase 1 Study Of Sunitinib With S-1 And Cisplatin For Gastric Cancer November 2007 March 2014
NCT00556049 Completed Phase 2 Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma December 2007 December 2014
NCT00577382 Completed Phase 2 SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma August 2007 August 2014
NCT00583063 Completed Early Phase 1 Interaction Study of Rapamycin and Sunitinib in Patients With Advanced Cancers October 2007 April 2008
NCT00589784 Completed Phase 2 Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma October 2007 October 2014
NCT00599313 Completed Phase 2 Phase II Sunitinib Prog Met AIPC March 2007 June 2009
NCT00616109 Completed Phase 2 Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC September 2007 January 2011
NCT00617253 Completed Phase 2 Combination of Recombinant Human IL-21 (rIL-21) and Sunitinib in Stage IV Renal Cell Carcinoma Patients July 12, 2007 June 30, 2008
NCT00619268 Completed Phase 2 Combination of Temsirolimus and Bevacizumab in Patient With Metastatic Renal Cell Carcinoma February 2008 February 2012
NCT00620347 Completed Phase 2 Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer March 2008 September 2012
NCT00662025 Completed Phase 2 Study Of Sunitinib With Capecitabine In Breast Cancer April 2008 May 2012
NCT00663559 Completed Phase 2 Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy February 2008 February 2010
NCT00668863 Completed Phase 2 Study Of Sunitinib With FOLFIRI In Colorectal Cancer May 2008 September 2010
NCT00678119 Completed Phase 2 Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment January 2008 May 2012
NCT00694096 Completed Phase 1 Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response September 2007 September 2014
NCT00695292 Completed Phase 2 Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer June 2008 September 2012
NCT00700258 Completed Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] February 13, 2008 December 28, 2021
NCT00709995 Completed Phase 2 A Study for Participants With Metastatic Renal Cell Carcinoma June 30, 2008 September 5, 2018
NCT00712504 Completed Phase 1 Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer July 2004 November 2007
NCT00720941 Completed Phase 3 Pazopanib Versus Sunitinib in the Treatment of Locally Advanced and/or Metastatic Renal Cell Carcinoma August 14, 2008 March 24, 2021
NCT00748358 Completed Phase 2 An Open-label Phase II Study With SUTENT in Patients Suffering From Hormone Refractory Prostate Cancer March 2008 April 2011
NCT00768144 Completed Phase 2 Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma September 2008 February 2013
NCT00783653 Completed Phase 1/Phase 2 Clinical Study of SU 11248 (Sutent) Combined With Standard Chemotherapy in Patients With FLT3 Mutated AML Over 60 Years August 2008
NCT00794950 Completed Phase 2 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma January 2009 August 22, 2016
NCT00798889 Completed N/A Rollover Protocol for Prior SU011248 Protocols March 2004 December 2011
NCT00843037 Completed Phase 2 Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma February 2009 March 14, 2022
NCT00847015 Completed Phase 2 Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer February 2009 November 2012
NCT00853372 Completed Phase 2 AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib May 28, 2009 June 25, 2019
NCT00861419 Completed Phase 1 To Evaluate the Safety, Tolerability and Pharmacokinetics of AMG 386 When Used in Combination With AMG 706, Bevacizumab, Sorafenib, or Sunitinib. December 2005
NCT00864864 Completed Early Phase 1 Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma May 2007 May 2013
NCT00884676 Completed Phase 1 Ixabepilone and Sunitinib Malate in Treating Patients With Progressive Advanced Solid Tumors November 2008 July 2015
NCT00886132 Completed Phase 2 A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands January 2007 December 2012
NCT00887575 Completed Phase 1/Phase 2 Neoadjuvant Sunitinib With Paclitaxel/Carboplatin in Patients With Triple-Negative Breast Cancer June 2009 September 2014
NCT00903175 Completed Phase 2 Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma October 2009 May 2015
NCT00967603 Completed Phase 2 Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer February 2008 January 2012
NCT00979966 Completed Phase 2 Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib July 2009
NCT00980213 Completed Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland September 2009 December 2013
NCT00981890 Completed Phase 1 Stereotactic Radiosurgery With Sunitinib for Brain Metastases July 2009 May 2022
NCT00537056 Completed N/A Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI October 2007 April 2012
NCT00089648 Completed Phase 2 SU011248 In The Treatment Of Patients With Bevacizumab (Avastin)-Refractory Metastatic Renal Cell Carcinoma December 2004 March 2008
NCT00092001 Completed Phase 2 Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer January 2005 March 2007
NCT00113516 Completed Phase 2 A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer September 2005 March 2009
NCT00226811 Completed Phase 2 An International Phase 2 Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Failing Chemotherapy January 2006 May 2008
NCT00265317 Completed Phase 2 A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone June 2006 January 2012
NCT00299741 Completed Phase 2 Study of SU11248 in Men With Advanced Prostate Cancer March 2006 June 2008
NCT00372424 Completed Phase 1 Study Of SU011248 In Combination With Docetaxel And Trastuzumab In Patients With Advanced Breast Cancer HER-2 Positive December 2006 September 2011
NCT00372775 Completed Phase 2 Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases March 2007 December 2009
NCT00373256 Completed Phase 3 A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer November 2006 August 2011
NCT00428220 Completed N/A A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study. July 2007 September 2014
NCT00430261 Completed Phase 2 Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma January 2007 October 2010
NCT00437372 Completed Phase 1 Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients March 2007 December 2010
NCT00453895 Completed Phase 2 Sunitinib in Refractory Adrenocortical Carcinoma July 2007 February 2012
NCT00457392 Completed Phase 3 A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone July 2007 December 2012
NCT00457691 Completed Phase 3 Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer June 2007 March 2010
NCT00471276 Completed Phase 2 Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer August 2007 June 2010
NCT00495872 Completed Phase 1 Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor June 2007
NCT01020630 Completed Phase 2 Sunitinib in Patients With Advanced Gastric Cancer and Treated With FOLFIRI November 2009 July 2013
NCT01024920 Completed Phase 2 Compare Safety and Efficacy of BIBF 1120 Versus Sunitinib. December 16, 2009 June 19, 2020
NCT01034878 Completed Phase 2 Sunitinib in Metastatic Renal Cancer December 2009 December 2014
NCT01064310 Completed Phase 3 Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer May 17, 2010 November 23, 2015
NCT01082809 Completed Phase 2 Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma March 2009 February 2012
NCT01100177 Completed Phase 2 Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients June 2009 January 2012
NCT01108445 Completed Phase 2 Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma September 2010 April 2015
NCT01121562 Completed Phase 2 Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors July 2010 November 2013
NCT01122615 Completed Phase 1 Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC) May 2010 July 2014
NCT01147822 Completed Phase 2 Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma May 19, 2010 September 3, 2021
NCT01164228 Completed Phase 2 Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery September 17, 2010 November 3, 2021
NCT01168440 Completed Phase 2 Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease March 2010 February 2011
NCT01254864 Completed Phase 2 Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies March 16, 2011 December 7, 2023
NCT01258348 Completed Phase 1 A Phase 1b Trial in Patients With Renal Cell Cancer July 2008 February 2012
NCT01265901 Completed Phase 3 IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma December 2010 July 2015
NCT01308034 Completed Phase 1 Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy March 2011 September 21, 2016
NCT01371201 Completed Phase 2 First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma December 22, 2011 April 20, 2021
NCT01402089 Completed Phase 4 Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients January 2012 November 2015
NCT01472081 Completed Phase 1 Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016) February 9, 2012 June 3, 2021
NCT01498835 Completed Phase 1 Safety Study of Preoperative Sunitinib and Radiation in Soft Tissue Sarcoma February 2012 February 2015
NCT01499121 Completed Phase 2 Study of Efficacy and Safety of Sunitinib Given on an Individualized Schedule May 2012 September 30, 2017
NCT01506336 Completed Phase 2 Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib October 2008 April 2012
NCT01517243 Completed Phase 2 Phase II Study of Alternating Sunitinib and Temsirolimus September 22, 2010 August 20, 2018
NCT01525550 Completed Phase 4 A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors June 6, 2012 July 26, 2018
NCT01548170 Completed Phase 1 To Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib April 2011 July 2011
NCT01551459 Completed Phase 2 A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma October 2010 November 2017
NCT01636908 Completed N/A Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies. August 2011 December 1, 2019
NCT01694277 Completed Phase 3 Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib April 2012 December 2020
NCT01718327 Completed Phase 2 A Study of Sunitinib in Patients With Advanced Cholangiocarcinoma September 1, 2011 November 17, 2016
NCT01743300 Completed Phase 1 The Influence of Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib in Cancer Patients July 2007 December 2010
NCT01824615 Completed Phase 2 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma January 2013 January 2016
NCT01829217 Completed Phase 2 Sunitinib in Never-Smokers With Lung Adenocarcinoma May 2013 January 2018
NCT01829841 Completed Phase 2 A Study of Famitinib in Patients With Advanced Metastatic Renal Cell Cancer May 2011 May 2016
NCT01934452 Completed Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients May 21, 2015 January 19, 2022
NCT01984242 Completed Phase 2 A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell Carcinoma January 8, 2014 January 8, 2019
NCT02058901 Completed Phase 1 Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors. July 2013 June 2019
NCT02060370 Completed Phase 2 Sunitinib Scheduling in Metastatic Renal Cell Carcinoma (mRCC) August 2014 January 2, 2019
NCT02164240 Completed Phase 1 Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST July 2014 May 2021
NCT02264665 Completed OPALINE : A Study Of Morbidity And Mortality At 2 Years May 12, 2015 November 18, 2019
NCT02282059 Completed The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors December 12, 2014 December 12, 2022
NCT02401815 Completed Phase 1/Phase 2 CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors March 6, 2015 May 11, 2020
NCT02420821 Completed Phase 3 A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC) May 20, 2015 December 13, 2021
NCT02432846 Completed Phase 2 Intratumoral Vaccination With Intuvax Pre-nephrectomy Followed by Sunitinib Post-nephrectomy vs Sunitinib Post-nephrectomy in Newly Diagnosed Metastatic Renal Cell Carcinoma (mRCC) April 2015 January 31, 2021
NCT02450123 Completed N/A Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors March 23, 2016 November 5, 2019
NCT02483247 Completed Phase 1 A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer September 2015 May 2019
NCT02555748 Completed Phase 4 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma November 17, 2015 January 16, 2020
NCT02623127 Completed Phase 2 A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma October 2015 October 2018
NCT02691793 Completed Phase 4 Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors November 20, 2017 November 19, 2019
NCT02713763 Completed Phase 2 Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib February 14, 2017 October 23, 2019
NCT02848768 Completed Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma December 2014
NCT02960906 Completed Phase 2 A BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naïve Metastatic Kidney Cancer May 31, 2017 February 15, 2021
NCT03066427 Completed Phase 2 Study to Evaluate Efficacy and Safety of Sunitinib in Renal Cell Carcinoma Progressed to 1L Immunotherapy Treatment. May 10, 2017 September 22, 2020
NCT03109015 Completed Phase 2 Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing September 27, 2017 October 8, 2019
NCT03170180 Completed Phase 2 Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer March 1, 2017 December 28, 2021
NCT03519542 Completed Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma November 2014 July 2018
NCT04033991 Completed Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. September 27, 2019 December 18, 2020
NCT04076787 Completed Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib September 1, 2018 September 2, 2018
NCT04115189 Completed A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA) December 13, 2019 December 2, 2020
NCT04175262 Completed Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments October 31, 2019 March 9, 2020
NCT04368546 Completed Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) November 1, 2015 March 1, 2020
NCT04633122 Completed Phase 2 A Study to Assess the Efficacy and Safety of DCC-2618 and Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib November 25, 2020 July 20, 2022
NCT04669366 Completed Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries January 20, 2021 July 31, 2021
NCT05745142 Completed A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine. February 23, 2023 February 23, 2023
NCT05949424 Not yet recruiting Phase 4 OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults May 2024 March 2025
NCT06032728 Not yet recruiting N/A Multimodal Recurrence Scoring System for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment October 1, 2023 October 1, 2033
NCT02688491 Not yet recruiting N/A A CpG-methylation-based Assay for Stratifying Stage III Clear Cell Renal Cell Carcinoma of Receiving Adjuvant Treatment July 2016 July 2026
NCT03899155 Recruiting Phase 2 Pan Tumor Rollover Study August 9, 2019 August 25, 2029
NCT05366816 Recruiting Phase 2 ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST October 17, 2023 December 2028
NCT03900793 Recruiting Phase 1 Losartan + Sunitinib in Treatment of Osteosarcoma August 26, 2019 February 2027
NCT02693535 Recruiting Phase 2 TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer March 14, 2016 December 31, 2025
NCT05734105 Recruiting Phase 3 A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib December 13, 2023 December 2027
NCT05043090 Recruiting Phase 3 Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC October 28, 2021 September 14, 2026
NCT03571438 Recruiting N/A Evaluation of a Promising New Combination of Protein Kinase Inhibitors on Organotypic Cultures of Human Renal Tumors October 16, 2017 September 30, 2024
NCT03297606 Recruiting Phase 2 Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) March 23, 2018 January 31, 2027
NCT05208047 Recruiting Phase 3 (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors April 14, 2022 September 2026
NCT03768063 Recruiting Phase 3 A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study February 28, 2019 July 5, 2028
NCT05024214 Recruiting Phase 1/Phase 2 Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors November 15, 2021 June 2024
NCT05245968 Recruiting Phase 1 A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) December 1, 2021 December 2025
NCT02925234 Recruiting Phase 2 The Drug Rediscovery Protocol (DRUP Trial) August 2016 December 2027
NCT00729833 Terminated Phase 1 Study Of CP-751,871 In Combination With Sunitinib In Patients With Advanced Solid Tumors September 2008 April 2013
NCT02315625 Terminated Phase 2 Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery April 8, 2015 May 22, 2019
NCT03878524 Terminated Phase 1 Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial April 1, 2020 December 10, 2020
NCT00982657 Terminated Phase 2 A Trial Of CVX-060, An Anti-Angiogenic COVX-Body, In Combination With Sunitinib In Patients With Advanced Renal Cell Carcinoma September 2009 March 2014
NCT00491738 Terminated Phase 2 A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R) August 2007
NCT01033981 Terminated Cost Effectiveness Of Sunitinib In Central America And Caribbean May 2010 February 2011
NCT01042795 Terminated Phase 2 Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy September 2009 January 2013
NCT01054911 Terminated N/A Evaluation of Patients With Bulky GIST Using Sunitinib October 2009 September 2015
NCT02560012 Terminated Phase 2 Personalized Targeted Inhibitors Treatment in Renal Cell Cancer January 4, 2016 July 27, 2017
NCT00676650 Terminated Phase 3 Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy July 2008 December 2011
NCT00434226 Terminated Phase 2 A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L) March 2007
NCT01185366 Terminated Phase 2 Everolimus Versus Sunitinib in Non-Clear Cell Renal Cell Carcinoma August 2010 September 9, 2019
NCT01216657 Terminated Phase 2 Trial of Single Agent Sunitinib for Patients With Chemo-refractory Metastatic Melanoma March 2009 May 2013
NCT00609622 Terminated Phase 2 Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer April 2008 July 2011
NCT00434356 Terminated Phase 2 A Study of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer (SABRE-B) March 2007
NCT00570908 Terminated Phase 2 Brain Mets - Capecitabine Plus Sunitinib and WBRT February 2009 September 2013
NCT00975806 Terminated Phase 1/Phase 2 Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma September 1, 2009 October 1, 2011
NCT01391130 Terminated Phase 2 A Study of LY2510924 and Sunitinib in Patients With Metastatic Renal Cell Carcinoma August 2011 February 2017
NCT00859456 Terminated Phase 2 Sunitinib in Certain Subtypes of Soft Tissue Sarcomas April 2007 February 2013
NCT02959554 Terminated Phase 2 Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control December 2016 January 2021
NCT01502228 Terminated N/A PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma October 2011 February 2014
NCT03140176 Terminated Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy. August 15, 2017 January 22, 2022
NCT01620216 Terminated Phase 2 Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia May 11, 2012 April 30, 2017
NCT00796861 Terminated Phase 2 Trial of Sunitinib for Refractory Malignant Ascites May 2007 April 2011
NCT01673386 Terminated Phase 2 A Subject Treatment Preference Study of Tivozanib Versus Sunitinib in Subjects With Metastatic RCC July 2012 January 2014
NCT00522249 Terminated Phase 1/Phase 2 Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC May 2007 July 2008
NCT01784978 Terminated Phase 2 Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer February 12, 2013 May 8, 2017
NCT03641326 Terminated Phase 2 Sunitinib in Sarcomas of the Central Nervous System February 21, 2019 April 2, 2021
NCT00496223 Terminated Phase 1/Phase 2 A Phase I/II Study of Sunitinib and Dacarbazine September 2006 June 2007
NCT00734851 Terminated Phase 2 Multimodality Phase II Study in Prostate Cancer December 2008 November 2014
NCT02071641 Terminated Phase 2 Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma October 2012 September 2016
NCT03729245 Terminated Phase 3 A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) December 18, 2018 October 19, 2022
NCT01069770 Unknown status Phase 2 Neoadjuvant Sunitinib Treatment for Metastatic Clear Cell Renal Cell Carcinoma (RCC) July 2009 June 2012
NCT02928575 Unknown status Phase 2 Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma August 2012 June 2017
NCT02230176 Unknown status Phase 2 Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II February 2015 October 2023
NCT04523272 Unknown status Phase 3 A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer August 25, 2020 June 2023
NCT03025893 Unknown status Phase 2/Phase 3 A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme August 31, 2018 January 1, 2022
NCT01803503 Unknown status Phase 2 Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors May 2013 April 2018
NCT02446795 Unknown status Phase 1/Phase 2 Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial November 2016 December 2017
NCT02689167 Unknown status Phase 2 Study to Assess Various Sunitinib Schedules in Renal Cell Carcinoma February 19, 2016 February 2024
NCT03449173 Unknown status Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial) March 2, 2017 May 31, 2022
NCT01216371 Unknown status Phase 2 Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT) October 2010 October 2015
NCT03862768 Unknown status N/A Role of Surgery in Patients With Focally Progressive Gastrointestinal Stromal Tumors (GISTs) After Imatinib Treatment July 2019 December 2021
NCT01219751 Unknown status Phase 2 Trial Of Sunitinib In Advanced Non-Clear Cell Type Renal Cell Carcinoma June 2008 September 2011
NCT00535379 Unknown status Phase 2 SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme October 2007 January 2011
NCT02239952 Unknown status N/A HGG-TCP (High Grade Glioma - Tumor Concentrations of Protein Kinase Inhibitors) November 2014 November 2021
NCT01286896 Unknown status Phase 1 Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors March 2011 December 2011
NCT03592199 Unknown status Phase 2 Biomarker Study of Pts With Metastatic ccRCC Undergoing Sequential Therapy With 1st Line Sunitinib and 2nd Line Axitinib December 11, 2017 December 11, 2022
NCT02919371 Unknown status Phase 1/Phase 2 Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA) December 2014 December 2021
NCT01731925 Unknown status Phase 2 A Study of Sunitinib Versus Placebo in Combination With Lanreotide in Patients With Progressive Advanced/Metastatic Midgut Carcinoid Tumors January 7, 2013 December 2017
NCT02398552 Unknown status Phase 2 A Phase II Trila of Sunitinib Schedule 4/2 vs. Shedule 2/1 as First Line Therapy in Metastatic Renal Cell Carcinoma. March 2015 March 2017
NCT00818350 Unknown status Phase 1/Phase 2 Activity Study of Sunitinib In Metastatic Pretreated Urothelial Cancer January 2009 January 2011
NCT00556205 Withdrawn Phase 2 Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma September 2009 September 2009
NCT03035630 Withdrawn Phase 2 Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma May 23, 2017 December 2020
NCT01070186 Withdrawn Phase 2 Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma October 2010
NCT03323710 Withdrawn Phase 2 Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma September 2018 December 2019
NCT02400385 Withdrawn Phase 2 A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma October 2014 December 2015